

Tunable performance of manganese oxide nanostructures as MRI contrast agents

J. Gallo

L. García-Hevia, M. Bañobre-López

Advanced (magnetic) Theranostic Nanostructures Lab, Department of Life Sciences, INL – International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga, 4715-330 Braga, Portugal
juan.gallo@inl.int

Magnetic resonance imaging (MRI) is a medical imaging technique perfectly suited for human healthcare applications. The lack of ionizing radiations, its high spatial/anatomical resolution and non-invasiveness make it an attractive tool for diagnostic purposes and to follow the progression of a disease/treatment.[1] To date the main limitation of MRI is its low sensitivity compared to radioactive-based and optical imaging modalities. To increase its sensitivity, contrast agents (CAs) are administered in about 50% of scans.[2] Clinically used CAs are based on a paramagnetic ion, Gd^{3+} , that due to its toxicity has to be administered strongly chelated to limit its interference with biological processes.[3] Other species are being studied as potential substitutes for Gd^{3+} chelates. MnO_2 nanostructures present several advantages over traditional Gd chelates. First, Mn is less toxic than Gd . Also, MnO_2 is not particularly active by MRI. This means that once administered it won't produce significant changes in MR images. However, MnO_2 is very sensitive to biologically relevant conditions. For example, under deregulated redox conditions, MnO_2 will be easily reduced into Mn^{2+} which is highly paramagnetic and significantly

enhances T1w MR signal.[4,5] This OFF-ON MR behavior can be exploited for diagnostic purposes. In this talk the synthesis and functional characterization of several Mn_xO_y nanostructures will be discussed as well as their combination with reporter molecules for other imaging techniques as a step further towards multimodal and unequivocal imaging diagnosis.

References

- [1] J. Gallo, N.J. Long, E.O. Aboagye, *Chem. Soc. Rev.* 42 (2013) 7816–7833
- [2] C. Tu, E.A. Osborne, A.Y. Louie, *Ann. Biomed. Eng.* 39 (2011) 1335–48
- [3] H. Ersoy, F.J. Rybicki, *J. Magn. Reson. Imaging.* 26 (2007) 1190–7
- [4] J. Gallo, N. Vasimalai, M.T. Fernandez-arguelles, M. Bañobre-López, *Dalt. Trans.* 45 (2016) 17672–17680
- [5] M. Bañobre-López, L. García-Hevia, F. Cerqueira, F. Rivadulla, J. Gallo, *Chem. Eur. J.*, DOI 10.1002/chem.201704861




Figure 1: Schematic representation of the aim and results of this work.